Financial Data and Key Metrics Changes - The company's net debt at the end of Q3 2023 was $17.7 billion, down from $18.4 billion at the end of 2022, while gross debt decreased to $20 billion from $21.2 billion [1] - The net debt-to-EBITDA ratio improved to 4.03x for Q3 2023, attributed to foreign exchange rate movements and free cash flow generation [1] - Non-GAAP revenue for Q3 2023 was approximately $3.9 billion, representing a 7% increase compared to Q3 2022 [7][29] - Non-GAAP gross profit margin improved to 53.5% in Q3 2023 from 53% in Q3 2022, driven by a favorable product mix [8] - Non-GAAP operating margin decreased to 26.5% in Q3 2023 from 27.2% in Q3 2022, primarily due to increased R&D expenses [9] Business Line Data and Key Metrics Changes - Revenue from AUSTEDO grew by 30% in Q3 2023, reaching $339 million, while AJOVY saw a 22% increase in revenue to $114 million [56][66] - The generics business in North America experienced a 15% revenue increase in Q3 2023, driven by higher sales of generic products [30] - The Europe segment's revenue remained flat in local currency terms, with strong growth in AJOVY offset by lower revenues from legacy brands [30] Market Data and Key Metrics Changes - Revenues from international markets increased by 20% in local currency terms, mainly due to higher revenue from generic products [31] - Approximately 46% of Q3 2023 revenue came from sales denominated in non-US dollar currencies, with foreign exchange rate movements negatively impacting revenues [21] Company Strategy and Development Direction - The company is focused on its "Pivot to Growth" strategy, emphasizing innovation and expanding its product pipeline, particularly in the generics and biosimilars markets [60][32] - A partnership with Sanofi was announced to advance the TL1A asset, which is seen as a significant growth opportunity [61][37] - The company aims to achieve a long-term financial target of a 2x net debt-to-EBITDA ratio by the end of 2027 [1] Management's Comments on Operating Environment and Future Outlook - Management expressed confidence in the company's ability to navigate market conditions and emphasized the importance of maintaining a competitive edge through R&D and product innovation [23][32] - The company is reframing its 2023 free cash flow guidance to a range of $1.7 billion to $2.1 billion, anticipating a sequential ramp-up in revenue and profitability [11] - Management acknowledged the impact of inflationary pressures but noted improvements in gross margins due to a favorable product mix [8][78] Other Important Information - The company reported a GAAP income of $80 million in Q3 2023, compared to $56 million in Q3 2022, primarily due to reduced tax expenses [20] - The company is actively seeking business development opportunities and licensing to expand its pipeline [12] Q&A Session Summary Question: Is the company comfortable with its current position or actively seeking to expand its pipeline? - Management confirmed that they are actively looking to expand their pipeline through business development and licensing opportunities [12] Question: Is there an expectation of large one-offs impacting guidance? - Management maintained guidance for AUSTEDO and noted that there are no significant changes expected in revenue lines, considering the seasonality of Q4 [5] Question: What is the status of the TL1A partnership and the $600 million milestone? - Management indicated that the partnership with Sanofi is progressing well and that the milestone is contingent on demonstrating competitive data [13][87] Question: What are the expectations for R&D expenses in Q4? - Management stated that R&D expenses are expected to remain elevated as part of their strategy to advance their innovative pipeline [16][90] Question: How does the company view the market conditions for generics? - Management acknowledged that market conditions are influenced by supply, demand, and competition, and emphasized the importance of timely product delivery to mitigate pricing pressures [23]

☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q (Exact name of registrant as specified in its charter) (State or other jurisdiction of OR TEVA PHARMACEUTICAL INDUSTRIES LIMITED ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-16174 incorporation or or ...

Potential to be first long-acting olanzapine with a favorable safety profile 官 H2 2026 - Phase III results $2.5bn Anti-TL1A (TEV-'574) H2 2024 – Phase II interim $28bn 14 | Target Updates Access programs launched (of 8 - 2025 target) cumulative regulatory submissions* (51% of 2025 target) reduction in scope 1 and 2 greenhouse gas emissions (52% of 2030 target) of employees trained on compliance policies** Winner: Best Company for Sustainability Reporting Finalist: Best Company for Social Responsibility dose ...

https://reportify-1252068037.cos.ap-beijing.myqcloud.com/media/production/s_m_content_8f541dc8773d15853a01aaed8cf3791f.html ...

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Q2 2023 Earnings Conference Call August 2, 2023 8:00 AM ET Company Participants Richard Francis - President & CEO Eli Kalif - CFO Dr. Eric Hughes - CMO, Head of R&D Sven Dethlefs - Head, North America Commercial Ran Meir - IR Conference Call Participants Jason Gerberry - Bank of America Umer Raffat - Evercore ISI Mikaela Franceschina - Barclays Ash Verma - UBS Thibault Boutherin - Morgan Stanley David Amsellem - Piper Sandler Chris Schott - J.P. Morgan Oper ...

Free Cash Flow by Quarters Free cash flow includes cash flow from operating activities, beneficial interest collected in exchange for securitized accounts receivables, proceeds from divestitures of businesses and other assets, net of cash used for capital investment. | 29 | 20.0 19.0 18.4 18.5 18.0 4.8 4.7 4.6 4.4 4.4 Q2 2022 Q3 2022 Q4 2022 Q1 2023 Q2 2023 | 30 | 1.0* 1.6 1.8 3.4 3.0 2.1 2.5 1.6 1.0 0.8 2.0 23 24 25 26 27 28 29 30 31 … 36 … 46 | --- | --- | --- | --- | |------------------------------------ ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-16174 TEVA PHARMACEUTICAL INDUSTRIES LIMITED (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organiz ...

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Q1 2023 Earnings Conference Call May 10, 2023 8:00 AM ET Company Participants Ran Meir - SVP, Investor Relations Richard Francis - President & CEO Eli Kalif - CFO Eric Hughes - Chief Medical Officer, Head of Research and Development Sven Dethlefs - Head, North America Commercial Conference Call Participants Hassan Aftab - Bank of America Merrill Lynch Umer Raffat - Evercore ISI Balaji Prasad - Barclays Ash Verma - UBS Nathan Rich - Goldman Sachs Chris Schot ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 FORM 10-Q ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 Commission file number 001-16174 TEVA PHARMACEUTICAL INDUSTRIES LIMITED (Exact name of registrant as specified in its charter) (State or other jurisdiction of incorporation or organi ...

Teva Pharmaceutical Industries Limited (NYSE:TEVA) Barclays Global Healthcare Conference March 14, 2023 10:15 AM ET Company Participants Eli Kalif - EVP and CFO Conference Call Participants Balaji Prasad - Barclays Balaji Prasad Good morning, everyone. My name is Balaji Prasad, I'm the Senior Analyst for the Barclays Specialty Pharmaceuticals coverage. For the next session of the day at the Barclays Annual Healthcare Conference. I have the pleasure of hosting Teva, and Eli Kalif, the Chief Financial Officer ...